Vision To Prevent and Cure Liver Disease Mission To advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists (including Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock, to name a few) to bring together those who had contributed to the field of hepatology. AASLD has grown to an international society responsible for all aspects of hepatology, and our annual meeting, The Liver Meeting®, has grown in attendance from 12 to over 9,500 physicians, surgeons, researchers, and allied health professionals from around the world. Hepatology has been recognized as a discipline only in the last few decades, and AASLD played a seminal and unifying role in focusing interest on hepatological problems, as well as the founding of other hepatological societies. Our three monthly journals, HEPATOLOGY, Liver Transplantation, and Clinical Liver Disease provide the latest research findings for hepatology and surgery of the liver. AASLD's membership includes ALL professionals dedicated to hepatobiliary discoveries and patient care. Mentoring, the sharing of knowledge, and dedication to professional growth and development are among the core values of AASLD and its members.


Claim this podcast

Remove this podcast

Play Latest Episode:

Title: Model to estimate survival in ambulatory patients with hepatocellular carcinoma

Model to estimate survival in ambulatory patients with hepatocellular carcinoma

October 4th, 2012

Drs. Stephen Harrison and W. Ray Kim discuss the paper: Model to estimate survival in ambulatory patients with hepatocellular carcinoma Abstract Survival… Go to Episode

Activation of IKK/NFκB signaling induces liver fibrosis

October 4th, 2012

Dr. Stephen Harrison talks to Drs. Thomas Wirth and Yoshiaki Suname about the paper: Hepatic activation of IKK/NF?B signaling induces liver fibrosis via… Go to Episode

Impact of disease severity on healthcare costs in patients with HCV

December 3rd, 2012

Abstract Hepatitis C virus (HCV) infection increases total healthcare costs but the effect of the severity of liver disease associated with chronic hepatitis… Go to Episode

Significance of Azathioprine Metabolites for the Maintenance of Remission in Autoimmune Hepatitis

December 18th, 2012

Drs. Stephen Harrison and Harpreet Dhaliwal Azathioprine (AZA) is used to maintain remission in autoimmune hepatitis (AIH), but up to 18% of patients… Go to Episode